Vandana Singh Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases An Alphabet-backed startup is poised to ...

Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer drugs delivered robust growth, though missed on its ...

The GSLV-F15 with the NVS-02 satellite lifted off from the spaceport’s second launch pad at 6.23 a.m. and 19 minutes later the GSLV-F15 with indigenous cryogenic stage placed the NVS-02 ...

TD Cowen analyst Steve Scala reiterated a Hold rating on Novartis (NVS – Research Report) today and set a price target of $125.00. The company’s shares opened today at $106.18. According to ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...